Modular, pumpless body-on-a-chip platform for the co-culture of GI tract epithelium and 3D primary liver tissue.
暂无分享,去创建一个
Mandy B. Esch | Michael L Shuler | Hidetaka Ueno | Mandy B Esch | M. Shuler | M. Esch | Dawn R Applegate | Hidetaka Ueno | Dawn R. Applegate
[1] Peter F. Davies,et al. Shear Stress Biology of the Endothelium , 2005, Annals of Biomedical Engineering.
[2] Jiajie Yu,et al. In vitro 3D human small intestinal villous model for drug permeability determination. , 2012, Biotechnology and bioengineering.
[3] D. Ingber,et al. Human gut-on-a-chip inhabited by microbial flora that experiences intestinal peristalsis-like motions and flow. , 2012, Lab on a chip.
[4] Malorye Allison,et al. Reinventing clinical trials , 2012, Nature Biotechnology.
[5] R. Hajar,et al. Animal Testing and Medicine , 2011, Heart views : the official journal of the Gulf Heart Association.
[6] G. Betton,et al. The predictivity of the toxicity of pharmaceuticals in humans from animal data--an interim assessment. , 1998, Toxicology letters.
[7] Tongtong Liu,et al. Evaluation of a novel in vitro Caco-2 hepatocyte hybrid system for predicting in vivo oral bioavailability. , 2004, Drug metabolism and disposition: the biological fate of chemicals.
[8] Mandy B. Esch,et al. How multi-organ microdevices can help foster drug development. , 2014, Advanced drug delivery reviews.
[9] H. Ferdowsian,et al. Ethical and Scientific Considerations Regarding Animal Testing and Research , 2011, PloS one.
[10] F. Sonntag,et al. A four-organ-chip for interconnected long-term co-culture of human intestine, liver, skin and kidney equivalents. , 2015, Lab on a chip.
[11] Yasuyuki Sakai,et al. Enhanced cytochrome P450 capacities of Caco-2 and Hep G2 cells in new coculture system under the static and perfused conditions : evidence for possible organ-to-organ interactions against exogenous stimuli , 2004 .
[12] J. Arrowsmith. Trial watch: Phase II failures: 2008–2010 , 2011, Nature Reviews Drug Discovery.
[13] Jiajie Yu,et al. Three dimensional human small intestine models for ADME-Tox studies. , 2014, Drug discovery today.
[14] Thomas Hartung,et al. Inflammatory findings on species extrapolations: humans are definitely no 70-kg mice , 2013, Archives of Toxicology.
[15] D. Shen,et al. Oral first‐pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A‐mediated metabolism , 1996, Clinical pharmacology and therapeutics.
[16] P. Sandercock,et al. Comparison of treatment effects between animal experiments and clinical trials: systematic review , 2006, BMJ : British Medical Journal.
[17] T. Miyakawa,et al. Genomic responses in mouse models poorly mimic human inflammatory diseases , 2013 .
[18] Mone Zaidi,et al. Molecular regulation of mechanotransduction. , 2005, Biochemical and biophysical research communications.
[19] Leslie Z. Benet,et al. Intestinal drug metabolism and antitransport processes : A potential paradigm shift in oral drug delivery , 1996 .
[20] E. Leclerc,et al. Investigation of ifosfamide nephrotoxicity induced in a liver–kidney co‐culture biochip , 2013, Biotechnology and bioengineering.
[21] Tim Morris,et al. Physiological Parameters in Laboratory Animals and Humans , 1993, Pharmaceutical Research.
[22] L. Griffith,et al. Bioreactor technologies to support liver function in vitro. , 2014, Advanced drug delivery reviews.
[23] Y. Berger,et al. The human intestinal epithelial cell line Caco-2; pharmacological and pharmacokinetic applications , 1995, Cell Biology and Toxicology.
[24] M. Shuler,et al. Quantification of chemical–polymer surface interactions in microfluidic cell culture devices , 2009, Biotechnology progress.
[25] Thomas Singer,et al. A long-term three dimensional liver co-culture system for improved prediction of clinically relevant drug-induced hepatotoxicity. , 2013, Toxicology and applied pharmacology.
[26] K. Hillgren,et al. In vitro systems for studying intestinal drug absorption , 1995, Medicinal research reviews.
[27] Aaron Sin,et al. Development of a Microscale Cell Culture Analog To Probe Naphthalene Toxicity , 2008, Biotechnology progress.
[28] S. Basu,et al. First-pass metabolism via UDP-glucuronosyltransferase: a barrier to oral bioavailability of phenolics. , 2011, Journal of pharmaceutical sciences.
[29] Paul S Price,et al. Modeling Interindividual Variation in Physiological Factors Used in PBPK Models of Humans , 2003, Critical reviews in toxicology.
[30] Michael L Shuler,et al. Incorporation of 3T3‐L1 Cells To Mimic Bioaccumulation in a Microscale Cell Culture Analog Device for Toxicity Studies , 2008, Biotechnology progress.
[31] Jiajie Yu,et al. On chip porous polymer membranes for integration of gastrointestinal tract epithelium with microfluidic ‘body-on-a-chip’ devices , 2012, Biomedical microdevices.
[32] J. March,et al. 3-D Intestinal Scaffolds for Evaluating the Therapeutic Potential of Probiotics , 2014, Molecular pharmaceutics.
[33] Kristina Luthman,et al. Caco-2 monolayers in experimental and theoretical predictions of drug transport1PII of original article: S0169-409X(96)00415-2. The article was originally published in Advanced Drug Delivery Reviews 22 (1996) 67–84.1 , 2001 .
[34] I. Cuthill,et al. Survey of the Quality of Experimental Design, Statistical Analysis and Reporting of Research Using Animals , 2009, PloS one.
[35] Jeffrey M. Perkel. LIFE SCIENCE TECHNOLOGIES: Animal-Free Toxicology: Sometimes, in Vitro is Better , 2012 .
[36] G. Nicolaysen,et al. Interstitial fluid volume: local regulatory mechanisms. , 1981, Physiological reviews.
[37] Mandy B. Esch,et al. Characterization of a gastrointestinal tract microscale cell culture analog used to predict drug toxicity , 2009, Biotechnology and bioengineering.
[38] Gretchen J. Mahler,et al. Characterization of Caco-2 and HT29-MTX cocultures in an in vitro digestion/cell culture model used to predict iron bioavailability. , 2009, The Journal of nutritional biochemistry.
[39] G Mannens,et al. Strategies for absorption screening in drug discovery and development. , 2001, Current topics in medicinal chemistry.
[40] Laurent Griscom,et al. Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. , 2012, Toxicology and applied pharmacology.
[41] Michael L Shuler,et al. A novel system for evaluation of drug mixtures for potential efficacy in treating multidrug resistant cancers , 2009, Biotechnology and bioengineering.
[42] Eric Leclerc,et al. First pass intestinal and liver metabolism of paracetamol in a microfluidic platform coupled with a mathematical modeling as a means of evaluating ADME processes in humans , 2014, Biotechnology and bioengineering.
[43] Jong Hwan Sung,et al. A microfluidic device for a pharmacokinetic-pharmacodynamic (PK-PD) model on a chip. , 2010, Lab on a chip.
[44] Michael L Shuler,et al. Multi-cellular 3D human primary liver cell culture elevates metabolic activity under fluidic flow. , 2015, Lab on a chip.
[45] J. Arrowsmith,et al. Trial Watch: Phase II and Phase III attrition rates 2011–2012 , 2013, Nature Reviews Drug Discovery.
[46] Hanry Yu,et al. Towards a human-on-chip: culturing multiple cell types on a chip with compartmentalized microenvironments. , 2009, Lab on a chip.
[47] K. Luthman,et al. Caco-2 monolayers in experimental and theoretical predictions of drug transport , 1996 .
[48] Mandy B. Esch,et al. Body-on-a-chip simulation with gastrointestinal tract and liver tissues suggests that ingested nanoparticles have the potential to cause liver injury. , 2014, Lab on a chip.